Dr. Aljitawi has broad background knowledge in hematopoietic stem cell transplantation, with specific expertise in umbilical cord blood transplantation. His research is focused on the development of translational research approaches to improve umbilical cord blood stem cell engraftment. He has specific expertise in umbilical cord blood stem cell homing and engraftment and the application of hyperbaric oxygen therapy as a modality to modulate erythropoietin to improve hematopoietic stem cell engraftment. He discovered the importance of erythropoietin (EPO) signaling through its receptor on UCB stem cell homing and engraftment. In addition, his laboratory is focused on developing in vitro 3D leukemia stromal- or extracellular matrix-based models for chemotherapy drug testing. More recently, his lab has been focused on studying decellularized Wharton's jelly matrix to create an extracellular matrix-based model to test leukemia cell responses to chemotherapy. In addition, he is investigating Wharton's jelly decellularized matrix for tissue regenerative medicine applications, including umbilical cord blood stem cell expansion and for tissue regenerative applications, including wound and bone healing.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.